if the commercial pathway comes forward, then there's a sustainable solution for sure.

Yeah, that's exactly, so that's exactly what I wanna ask about.

So yeah, I mean, that looks like, okay, we know that Enlorem raises money from partners like Biogen, for instance, who helps with the colloquium.

You raise money from individuals and you also do raise money through some research deals.

And this would open up the possibility of continuing research and then maybe a drug being sold that you would get royalties from or something.

That's more like a classic biotech business model.

And along those lines, right, so we saw two deals that NLORM signed this summer.

And here's the progress that we're making and the potential impact on the hope that we can provide to our patients.

We want the 411,

everything we can say.

So it started quite a while ago.

I had gone to a conference, the INSAR conference.

It's a conference for research on autism.

And I was pretty new to the field at the time.

And I met a researcher there.

So as you were doing this podcast, what surprised you? Well, I mean, so when I read the paper